Following Recursion’s presentation at a Q&A session at the firm’s healthcare conference, JPMorgan said the company’s updates were “largely in line/as anticipated.” The analyst, who continues to believe it will take definitive clinical wins from Recursion’s pipeline to validate the platform and “for shares to become constructive by extension,” maintains a Neutral ratring on the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Recursion Pharmaceuticals Showcases Progress at JP Morgan Conference
- Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals today
- Recursion Pharmaceuticals price target lowered to $10 from $12 at KeyBanc
- Recursion announces two oncology drugs advancing to clinical trials
- Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA